Current Hematologic Malignancy Reports (2024) 19:151
https://doi.org/10.1007/s11899-024-00734-x

CORRECTION

Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

Tariq Kewan[1] · Maximillian Stahl[2] · Jan Philipp Bewersdorf[3] · Amer M. Zeidan[1]

Published online: 18 May 2024

Correction to: Current Hematologic Malignancy Reports
https://doi.org/10.1007/s11899-024-00733-y

The original online version of this article was revised to update the following statement (changes are in bold font):

FROM:
"In another randomized placebo-controlled trial, 130 patients with hemoglobin less than 10 g/dL were randomized in a 2:1 fashion to receive darbepoetin 450 IU/kg/week or placebo. Erythroid response based on the International Working Group (IWG) 2006 criteria was 45.9% in the darbepoetin arm compared to 4.4% for placebo ($p < 0.0001$) [36]."

Replace with:
"In another randomized placebo-controlled trial, 130 patients with hemoglobin less than 10 g/dL were randomized in a 2:1 fashion to receive **epoetin-alfa** 450 IU/kg/week or placebo. Erythroid response based on the International Working Group (IWG) 2006 criteria was 45.9% in the **epoetin** arm compared to 4.4% for placebo ($p < 0.0001$) [**34**]."

FROM:
"The findings revealed significant advantages associated with luspatercept treatment: approximately 38% of patients treated with luspatercept achieved transfusion independence, a notably higher rate than the 13% observed in the epoetin alfa group. Furthermore, luspatercept demonstrated a substantial reduction in the median red blood cell transfusion burden by 44%, whereas the epoetin alfa group showed a reduction of 13%, underscoring the superior efficacy of luspatercept in reducing transfusion requirements."

Replace with:
"The findings revealed significant advantages associated with luspatercept treatment: approximately **59%** of patients treated with luspatercept achieved **the primary endpoint of** transfusion independence **and a concurrent mean hemoglobin increase of at least 1.5 g/dL**, a notably higher rate than the **31%** observed in the epoetin alfa group."

The statement "Furthermore, luspatercept demonstrated a substantial reduction in the median red blood cell transfusion burden by 44%, whereas the epoetin alfa group showed a reduction of 13%, underscoring the superior efficacy of luspatercept in reducing transfusion requirements." was removed.

The original article has been corrected.

The original article can be found online at https://doi.org/10.1007/s11899-024-00733-y.

✉ Amer M. Zeidan
amer.zeidan@yale.edu

[1] Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA

[2] Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

[3] Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA